Company Number: 14738217

Analysis Date: 2025-07-29 13:06 UTC

Financial Health Assessment Report: CHEVRON RESEARCH LIMITED

---

1. Financial Health Score: D

Explanation:
The company is showing signs of financial distress, primarily due to persistent negative net current assets and shareholders’ funds, indicating a working capital deficit and accumulated losses. While it remains active and not in liquidation, the financial "vital signs" suggest ongoing liquidity challenges and reliance on director support to continue operations.

---

2. Key Vital Signs

Metric	2023-24 (£)	2024-25 (£)	Interpretation
Current Assets	3,610	8,690	Low but increasing; mostly cash
Cash at Bank	3,610	7,847	Improved cash position but still limited
Debtors	0	843	Minimal trade receivables, indicating low sales
Current Liabilities	29,618	32,814	High and increasing short-term obligations
Net Current Assets	-26,008	-24,124	Negative; working capital deficit persists
Shareholders’ Funds	-26,010	-24,126	Negative equity; accumulated losses present
Operating Activity	No employees	No employees	No staff costs reported; possibly a start-up or minimal activity

Interpretation of Vital Signs:

• Negative Working Capital: The company’s current liabilities significantly exceed its current assets by over £24k, a "symptom" of liquidity strain. This means the firm may struggle to meet short-term obligations from its liquid resources.
• Negative Equity: Shareholders’ funds are negative, reflecting accumulated losses or initial funding shortfalls. This is akin to a patient with a chronic condition that has not yet been stabilized.
• Cash Position: Cash has improved over the year from £3,610 to £7,847, suggesting some inflows or financing, but remains low relative to liabilities.
• No Employees: The absence of employees may imply limited operational scale or reliance on directors for business activity.
• Director Support: The director’s note on going concern highlights that the company is dependent on continued support from its director to survive, which is a warning sign of underlying financial fragility.

---

3. Diagnosis

Underlying Health Condition:
Chevron Research Limited is a very young private limited company, incorporated in March 2023, operating in market research and public opinion polling. The financial "symptoms"—negative net current assets, negative equity, and reliance on director support—are typical of an early-stage business that has yet to generate sustainable profits or build a positive financial foundation.

The company’s balance sheet shows a persistent working capital deficit, indicating that current liabilities exceed current liquid assets, which poses a risk to meeting short-term obligations without additional funding or improved cash flows. The director's acknowledgment of going concern based on support from the director suggests the company could face financial distress if this support ceases.

No audit was required due to its small company status, and accounts are prepared under the small companies regime with standard accounting policies.

Summary of Financial Health:

• Liquidity Risk: Elevated, due to negative working capital.
• Solvency Risk: Indicated by negative equity; capital structure is weak.
• Operational Scale: Minimal, no employees reported, small asset base.
• Going Concern: Dependent on director's financial support.

---

4. Recommendations

To improve financial wellness and stabilize the company's "health," the following actions are advised:

1. Increase Working Capital:

   • Inject additional capital or secure short-term financing to cover current liabilities and avoid liquidity crises.
   • Consider directors’ loans or equity funding to improve cash reserves.

2. Enhance Revenue Generation:

   • Develop and execute a robust sales and marketing strategy to increase turnover and create positive cash inflows.
   • Build a receivables pipeline to improve debtor balances and future cash flow.

3. Cost Management:

   • Maintain lean operations to minimize overheads until revenue streams stabilize.
   • Avoid incurring additional liabilities that cannot be met without new income.

4. Financial Monitoring and Reporting:

   • Implement monthly cash flow forecasting to anticipate liquidity needs.
   • Regularly review financial performance against budgets to detect early "symptoms" of distress.

5. Director Support Contingency:

   • Formalize arrangements with directors and clearly document any financial support or loans to ensure transparency and governance compliance.

6. Strategic Planning:

   • Consider partnerships or joint ventures to share risks and resources.
   • Evaluate potential for scaling operations prudently once financial stability improves.

---

Medical Analogy Summary:
Chevron Research Limited currently exhibits "symptoms of financial distress" akin to a patient with a weakened immune system—low liquidity and negative equity. The director’s support acts as a vital lifeline, much like a critical medication maintaining stability. Without intervention to boost working capital and generate sustainable revenue, the company's financial health remains precarious.

---